title: Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy.
abstract: Menopausal symptoms affect a significant portion of women. Traditional treatment with manufactured hormone therapy can alleviate these symptoms, but many women and their health care providers are concerned about the risks, such as venous thromboembolism and certain types of cancer, demonstrated with manufactured hormone therapy. Compounded bioidentical hormone therapy has been proposed and is often used as a solution for these concerns. Despite this use, no data are currently available to support the claims that compounded bioidentical hormone therapy is a safer or more efficacious option compared with manufactured hormone therapy. A common misperception is that all manufactured products consist of synthetic hormones and all compounded medications consist of natural hormones; however, in fact, significant overlap exists. Several key stakeholder organizations have issued statements expressing concern about the lack of evidence regarding the efficacy and safety of compounded bioidentical hormone therapy, in addition to concerns regarding prescribing patterns. The Women's Health Practice and Research Network of the American College of Clinical Pharmacy recommends against the consistent use of compounded bioidentical hormones as a safer option compared with manufactured therapy and supports the statements of other key organizations, acknowledging the need for more robust clinical studies to evaluate the potential advantages and disadvantages of compounded bioidentical products compared with manufactured products.
authors.affiliation: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: McBane
authors.forename: Laura M
authors.initials: LM
authors.lastname: Borgelt
authors.forename: Kylie N
authors.initials: KN
authors.lastname: Barnes
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Westberg
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Lodise
authors.forename: Martha
authors.initials: M
authors.lastname: Stassinos
mesh_terms: D000328:Adult; D004339:Drug Compounding; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D010353:Patient Education as Topic; D016387:Women's Health
keywords: bioidentical hormones; compounding; estrogen; hormone therapy; menopause; progestogen